Swiss Childhood Cancer Registry: Annual Report 2013/2014 by Schindler, Matthias et al.
sw
is
s c
h
ild
h
o
o
d
 c
an
ce
r r
eg
is
tr
y
annual report 2013-2014

Swiss Childhood Cancer Registry 
Annual Report 2013/2014
For the Swiss Childhood Cancer Registry
Matthias Schindler 
Vera Mitter
Verena Pfeiffer
Shelagh Redmond
Priska Wölﬂi
Rahel Kuonen
Grit Sommer
Marlen Spring
Parvinder Singh
Gisela Michel
Claudia Kuehni
For the Swiss Paediatric Oncology Group
Felix Niggli
Heinz Hengartner
Maja Beck Popovic
Nicolas von der Weid
Isabelle Lamontagne-Müller
Bern, March 2015
Publisher:
Swiss Childhood Cancer Registry
Claudia E. Kuehni 
Address: 
Institute of Social and Preventive Medicine
University of Bern
Finkenhubelweg 11
CH-3012 Bern
Switzerland
Tel. +41 (0)31 631 56 70  
Tel. +41 (0)31 631 38 99
E-mail kinderkrebsregister@ispm.unibe.ch
www.childhoodcancerregistry.ch
www.kinderkrebsregister.ch
www.registretumeursenfants.ch
www.registrotumouripediatrici.ch
Bern, Swiss Childhood Cancer Registry
4
51. Introduction 7
2. Organisation of the Swiss Childhood Cancer Registry 9
 2.1 Institute of Social and Preventive Medicine (ISPM), University of Bern 9
 2.2 Swiss Paediatric Oncology Group (SPOG) 10
 2.3 General information 11
3. Routine Analyses 13
 3.1 Overview 13
 3.2 All cases registered in the SCCR (N=8957) 13
 3.3 Swiss residents aged 0-14 years at diagnosis (N=6371) 15
 3.4 Swiss residents aged 15-20 years at diagnosis (N=450) 21
4. Research projects on childhood cancer 23
 4.1 Swiss Childhood Cancer Survivor Study (SCCSS) 24
 4.2 Follow-up Care After Childhood and Young Adult Cancer (CCFU) 25
 4.3 PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) 26
 4.4 PanCare Studies in Fertility and Ototoxicity to Improve Quality of Life after Cancer 
  during Childhood, Adolescence and Young Adulthood (PanCareLIFE) 27
 4.5 Risk of Cancer and Long-Term Mortality in Children Treated with 
  Growth Hormone: Swiss Participation in the EU FP7 Project (SAGhE) 27
 4.6 Mortality and Second Primary Cancers after Cancer in Childhood and Adolescence 28
 4.7 Fertility after Chemo- and Radiotherapy in Childhood and Adolescence, FeCt – Multicentre Offspring Study 28
 4.8 Parents of Long-Term Childhood Cancer Survivors 29
 4.9 Effectiveness of Transition from Paediatric to Adult Care after Childhood Cancer 30
 4.10 Childhood Cancer and Vicinity of Residence to Petrol Stations and Roads: 
  Census-Based Nationwide Cohort Study (PETROL) 30
 4.11 Childhood Cancer and Geographically Deﬁned Exposures in Switzerland: 
  A Census-Based Nationwide Cohort Study 31
 4.12 The Role of Population Mixing and Exposure to Infections 
  in the Aetiology of Childhood Leukaemia: A National Cohort Study 31
 4.13 The Spatial Epidemiology of Childhood Cancer in Switzerland 32
5. Publications 33
 5.1 Publications in peer-reviewed journals 33
 5.2 Publications in other journals 35
 5.3 Publications in lay journals 35
 5.4 Reports 36
6. Appendix: Classiﬁcation of cancer diagnoses 37
Table of contents
6
7Swiss Childhood Cancer Registry Annual Report 2013/2014  lntroduction
The Swiss Childhood Cancer Registry (SCCR) is the na-
tional population-based cancer registry for children and 
adolescents in Switzerland. New cancer diagnoses, clinical 
information, details on treatment and long-term follow-up 
(survival, second primary neoplasms and late effects) have 
been registered in the SCCR since 1976. With many asso-
ciated research projects and through close collaboration 
with clinicians it contributes to understanding the causes of 
cancer in children, improving follow-up care and reducing 
late effects.
The SCCR is located at the Institute of Social and Preven-
tive Medicine (ISPM) at the University of Bern. It is operated 
jointly by the Swiss Paediatric Oncology Group (SPOG) and 
the University of Bern. Since 1976, all nine Swiss paediat-
ric haematology-oncology centres report newly diagnosed 
cases to the registry and send annual updates on clinical 
follow-up. Since 2007, the SCCR collects supplementary 
data also from other sources, including cantonal cancer 
registries, other hospitals, pathology laboratories and the 
Swiss Federal Statistical Ofﬁce (SFSO). As of 31st December 
2013, data from 8957 cases (diagnosed in 8608 patients) 
have been registered. 
The SCCR is authorized to collect non-anonymised 
data. The permission has been issued in 2007 by the Federal 
Commission of Experts for Professional Secrecy in Medical 
Research (Eidgenössische Expertenkommission für das Be-
rufsgeheimnis in der medizinischen Forschung). Since 2014 
the new act on human research is in place; the SCCR got 
a new authorization issued by the ethics committee of the 
canton of Bern in July 2014.
The SCCR is an associated member of the National In-
stitute for Cancer Epidemiology and Registration (NICER), 
of the European Network of Cancer Registries (ENCR) and 
of the International Association of Cancer Registries (IACR), 
and collaborates with childhood cancer registries through-
out Europe.
This sixth annual report covers the routine analyses 
of all children diagnosed between 1st January 1976 and 31st 
December 2013. Activities, projects and publications of the 
SCCR are described for the years 2013 and 2014. The re-
port contains:
• An overview of the organisation and team of the 
SCCR, SPOG and the participating paediatric haema-
tology-oncology centres (Chapter 2)
• A summary of the data collected in the registry up to 
31st December 2013 (Chapter 3)
• A list of current research projects of the SCCR (Chapter 4)
• A list of publications (Chapter 5)
Our website (www.childhoodcancerregistry.ch) contains 
further information, including past annual reports and sci-
entiﬁc publications.
We would like to thank all the children and their fam-
ilies, and all adolescent and adult childhood cancer survi-
vors, for allowing us to collect their data. We also thank the 
physicians and data managers of the Swiss Paediatric On-
cology Group for their excellent collaboration. Our thanks 
also go to the cantonal cancer registries, the National In-
stitute for Cancer Epidemiology and Registration (NICER), 
the Swiss Federal Statistical Ofﬁce (SFSO), the Federal Ofﬁce 
of Public Health (FOPH) and the pathology laboratories for 
their cooperation. Finally, we thank our supporters for their 
generous contributions.
1. Introduction
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2. Organisation of the Swiss Childhood Cancer Registry
The Swiss Childhood Cancer Registry (SCCR) is a member of the Swiss Paediatric Oncology Group (SPOG) 
and is organised as a joint operation of the Institute of Social and Preventive Medicine (ISPM) at the Uni-
versity of Bern and the SPOG.
2.1 Institute of Social and Preventive Medicine (ISPM), University of Bern
Direction
Claudia Kuehni, Prof MD Head of SCCR claudia.kuehni@ispm.unibe.ch
Gisela Michel, Prof PhD Vice head of SCCR gisela.michel@unilu.ch
 
Swiss Childhood Cancer Registry
Verena Pfeiffer, PhD Project coordinator SCCR verena.pfeiffer@ispm.unibe.ch
Katharina Flandera Administration katharina.ﬂandera@ispm.unibe.ch
Shelagh Redmond, PhD Diagnostic coding 
Parvinder Singh Statistics 
Marlen Spring Data management 
Erika Brantschen Archive 
 
Trust Centre 
Christina Krenger Data management 
 
Informatics and database support 
Priska Wölﬂi Database support 
 
Research projects 
Ben Spycher, PhD Senior research fellow, Project manager  
Grit Sommer, PhD Senior research fellow, Project manager  
Rahel Kuonen, MSc Senior research fellow, Project manager 
Christian Kreis, PhD Senior research fellow 
Rahel Kasteler, M med PhD student 
Judith Lupatsch, MSc PhD student 
Matthias Schindler, MSc PhD student 
Annette Weiss, MSc PhD student 
Laura Wengenroth, MSc PhD student 
Swiss Childhood Cancer Registry
Institute of 
Social and Preventive Medicine
Finkenhubelweg 11
CH-3012 Bern
Switzerland
Tel. +41 (0)31 631 48 61
www.kinderkrebsregister.ch
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2.2 Swiss Paediatric Oncology Group (SPOG)
SPOG Executive Board 
Felix Niggli, Prof MD President 
Heinz Hengartner, MD Vice president 
Maja Beck Popovic, PD MD Committee Member 
SPOG Ofﬁce in Bern 
Isabelle Lamontagne-Müller, MSc Managing director isabelle.lamontagne@spog.ch
Barbara Böttcher, PhD Quality assurance  
  Regulatory affairs 
Marie B. Lefevre Sangiano, MSc Regulatory affairs 
Martina Peluso, MSc Regulatory affairs  
Olivier Leroy, PhD Regulatory affairs 
Barbara Kilchhofer Director’s assistant 
Participating centres (paediatric haematology-oncology)
  Head of Division Local Data Manager
Aarau 
Kinderklinik, Kantonsspital Aarau R. Angst, MD C. Anderegg, MSc
Basel 
Universitäts-Kinderspital  N. von der Weid, Prof MD V. Stahel
beider Basel [UKBB] 
Bern 
Universitätsklinik für  K. Leibundgut, Prof MD F. Julmy 
Kinderheilkunde, Inselspital  N. Beusch
Genève 
Hôpital des Enfants, Hôpitaux  M. Ansari, PD MD R. Lo Piccolo
Universitaires de Genève [HUG] 
Lausanne 
Service de Pédiatrie, Centre Hospi- M. Beck Popovic, PD MD R.-E. Garcia, MD
talier Universitaire Vaudois [CHUV] 
Bellinzona 
Reparto di Pediatria, Ospedale 
S. Giovanni, Bellinzona P. Brazzola, MD P. Brazzola, MD
Luzern 
Kinderspital, Kantonsspital Luzern J. Rischewski, PD MD N. Lanz
St.Gallen 
Ostschweizer Kinderspital J. Greiner-Lang, MD F. Hochreutener
Zürich  
Universitäts-Kinderspital, Zürich F. Niggli, Prof MD H. Markiewicz
  M. Grotzer, Prof MD A. Reinberg
   R. Siegenthaler
SPOG Ofﬁce 
Efﬁngerstrasse 40, 3008 Bern
Tel. +41 (0)31 389 91 89 
Fax +41 (0)31 389 92 00 
www.spog.ch
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2.3 General information
Aims 
The Swiss Childhood Cancer Registry collects information 
on the diagnosis, treatment and follow-up of children and 
adolescents with cancer in Switzerland and provides data for 
national and international statistics and research projects. 
It aims: 
• To collect representative, population-based data on 
cancer in children and adolescents in Switzerland 
(cancer incidence, prevalence, time trends, regional dis-
tribution and survival rates)
• To document diagnostic evaluations, treatment and 
participation in clinical trials
• To describe short-term and long-term prognosis 
(mortality, morbidity and quality of life) after cancer in 
childhood and adolescence
• To provide a research platform for clinical, epidemio-
logical and basic research
It thus contributes to:
• Research into the aetiology of cancer in children and 
adolescents.
• Planning of health services 
• Continuous improvement of treatment
• Identifying possible late effects of therapy, with the 
aim to diagnose and treat them early and prevent 
them in the future 
Inclusion criteria
The SCCR registers all children and adolescents aged 0 
to 20 years, resident or treated in Switzerland, diagnosed 
with:
• Acute and chronic leukaemias, including myelodysplas-
tic syndrome
• Lymphomas
• Malignant solid tumours
• Central nervous system tumours (CNS), malignant and 
benign tumours 
• Langerhans cell histiocytosis (LCH) 
Since 2014 it also registers children and adolescents diag-
nosed with:
• Aggressive ﬁbromatosis (ICD-O-3M code 8821/1)
• Benign/mature teratoma (ICD-O-3M code 9080/0)
• Mesoblastic nephroma (ICD-O-3M code 8960/1)
• Severe aplastic anaemia (ICD-10 D61.9)
• Neoplasms of the liver, histologically proven, but no 
malformations
Children and adolescents who are not Swiss residents 
but are diagnosed or treated in Switzerland are registered, 
but they are excluded from analyses of incidence and sur-
vival.
Sources of data
Data on children and adolescents with cancer are collected 
from several sources, including: 
• The nine Swiss centres for paediatric oncology and 
haematology (Chapter 2.2)
• Other hospitals
• Cantonal cancer registries, represented by the National 
Institute for Cancer Epidemiology and Registration 
(NICER)
• Clinical and epidemiological registries (e.g. brain 
tumour registry, bone tumour registry, Swiss growth 
registry etc.)
• The Swiss Federal Statistical Ofﬁce (SFSO; Swiss mortal-
ity statistics)
• Pathology laboratories 
Most children are reported by one of the nine Swiss cen-
tres for paediatric oncology and haematology. Local data 
managers complete forms for all newly diagnosed patients. 
Basic information on diagnosis is later completed with infor-
mation on treatments, remissions, relapses, transplantations 
and health outcomes. These forms are sent to the SCCR and 
information is entered into the database. Important medical 
documents (e.g. pathology reports) are scanned and stored 
electronically using a pseudonym. Paper copies are de-
stroyed. Information on Swiss residency is validated through 
municipal population registers.
For the ﬁrst ﬁve to ten years after diagnosis follow-up 
data is extracted annually from patients’ hospital records 
by the local data managers in all paediatric oncology and 
haematology centres (page 13, Chapter 3.2). To assess out-
comes after the children have left the clinic, patients are 
contacted directly with a questionnaire (page 24, Chap-
ter 4.1: Swiss Childhood Cancer Survivor Study) and data 
is linked to mortality records (SFSO) and to records from 
cantonal cancer registries (page 28, Chapter 4.6: Mortality 
and second primary cancers after cancer in childhood and 
adolescence). Life status update is assessed through com-
munity registries. For children not treated in a paediatric 
oncology and haematology centre, clinical follow-up from 
hospitals is often not available, but long-term epidemiolog-
ical follow-up is done via questionnaires and by assessment 
of second primary neoplasms and mortality as for the oth-
er patients and life status update via community registries 
(page 13, Chapter 3.2).
Clinical database
The current SCCR database was set up in 2007. The follow-
ing information is routinely collected:
• Tumour diagnosis, date of diagnosis, morphology, 
topography, stage, metastases
• Other diagnoses (relevant pre-existing conditions)
• Relevant laboratory and clinical data
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• Treatment (clinical trial participation, chemotherapy, 
radiotherapy, surgical intervention, bone marrow trans-
plantation) and treatment centres involved
• Follow-up data (changes of treatment, remissions, 
relapses, survival/death and cause of death)
• Late adverse outcomes (e.g. cardiovascular diseases, 
second primary neoplasms and endocrine disorders) 
Trust centre
Since 2010, personal information (name and address) is 
stored in a separate database in the trust centre. The trust 
centre validates addresses, residence status, nationality, and 
vital status via community registers. This personal informa-
tion is separated strictly from clinical information of the 
SCCR database. The following data is collected: 
• Patient name, address of residence at time of diagnosis, 
 current address of residence
• Date of birth, sex, ﬁrst language
• Country of residence and nationality at time of diagnosis
• Vital status and date of death
• Parental profession, parental date of birth
Tumour coding
All tumours are coded according to the following interna-
tional classiﬁcation systems (see appendix): 
• International Classiﬁcation of Childhood Cancer, third 
edition (ICCC-3) 
• International Classiﬁcation of Diseases for Oncology, 
third edition (ICD-O-3) 
• International Classiﬁcation of Diseases and Related 
Health Problems, tenth revision (ICD-10) 
In the annual report, the main diagnostic groups of the 
ICCC-3 are used: 
I.  Leukaemias, myeloproliferative diseases, and myelodys-
 plastic diseases
II.  Lymphomas and reticuloendothelial neoplasms
III.  CNS and miscellaneous intracranial and intraspinal 
 neoplasms
IV.  Neuroblastoma and other peripheral nervous cell tumours
V.  Retinoblastoma
VI. Renal tumours
VII. Hepatic tumours
VIII. Malignant bone tumours
IX.  Soft tissue and other extraosseous sarcomas
X. Germ cell tumours, trophoblastic tumours, and neo-
 plasms of gonads
XI.  Other malignant epithelial neoplasms and malignant  
 melanomas
XII. Other speciﬁed and unspeciﬁed malignant neoplasms 
Langerhans cell histiocytosis (LCH), which is not included in 
ICCC-3, is reported separately.
Data protection
In 2004, the SCCR received a special authorisation (Son-
derbewilligung) from the Swiss Federal Commission of Ex-
perts for Professional Secrecy in Medical Research. Starting 
from June 2007, a general authorization (Registerbewilli-
gung) permitted the collection data from paediatric cancer 
patients (children and adolescents) throughout Switzerland 
after obtaining written, oral or silent consent. 
Since January 2014 the new Human Research Act and its 
three ordinances are in place. Out of those three ordinanc-
es the ordinance on Human Research with the exception 
of Clinical Trials provides the new framework for the SCCR. 
Instead of the Swiss Federal Commission of Experts for Pro-
fessional Secrecy in Medical Research, data collection and 
storage by SCCR now require an authorisation by the ethics 
committee of the canton of Bern. The general authorization 
(Registerbewilligung) has been replaced in July 2014 by an 
approval from the ethics committee of the canton of Bern. 
Funding
The SCCR thanks the following supporters for their ﬁ-
nancial contributions towards the daily operation and the 
continuous development of the registry. Supporters of sci-
entiﬁc research projects are listed in Table 7 (page 23).
Main funding sources 2013/2014
• Schweizerische Konferenz der kantonalen Gesundheits-
 direktoren und -direktorinnen (GDK)
• Schweizerische Pädiatrische Onkologie Gruppe (SPOG) 
• Krebsforschung Schweiz 
• Kinderkrebshilfe Schweiz 
• Stiftung für krebskranke Kinder Regio Basiliensis (2013) 
• Ernst Göhner Stiftung 
• Interpharma
• AXA-Winterthur 
Other funding sources 2013/2014
• National Institute for Cancer Epidemiology and Regis-
tration (NICER)
• Novartis  
• CSL Behring 
• Stiftung zur Krebsbekämpfung
• Erwin Braun Stiftung Basel
• Henriette Dubach Stiftung
• Innova Krankenkasse
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3.1 Overview
The SCCR registers all tumours diagnosed and treat-
ed in Switzerland, classiﬁed according to the ICCC-3 and 
Langerhans cell histiocytoses (LCH) in patients aged 0 to 
20 years at time of diagnosis. This annual report covers 
the time period from 1st January 1976 until 31st December 
2013. The additional disorders, which are registered since 
2014 (see inclusion criteria under paragraph 2.3), have not 
been included in the following analyses. Incidence rates are 
calculated based on the number of primary neoplasms (cas-
es). The number of cases slightly exceeds the number of pa-
tients because patients with more than one primary tumour 
diagnosed before age 20 years are counted separately for 
each new tumour. 
The section on routine analyses includes three chapters:
Chapter 3.2 presents data on all cases registered in the 
SCCR. This includes cases resident in Switzerland or abroad, 
who were diagnosed or treated in Switzerland. 
Chapter 3.3 presents data on cases resident in Switzer-
land, aged 0 to 14 years at diagnosis. This correspondents 
to the age group usually covered in international publica-
tions. Therefore, tables and ﬁgures can be compared with 
data from other countries. Because registration in Switzer-
land is more than 95% complete for this age range with 
estimated incidence and survival rates close to their true 
value.
Chapter 3.4 presents data on cases resident in Switzer-
land, aged 15 to 20 years at diagnosis. Patients of this age 
group are treated in a large number and variety of clinics 
and therefore registration is less complete. Ultimately, inci-
dence rates cannot be calculated for this age group.
3.2 All cases registered in the SCCR (N=8957)
This chapter describes data from all cases diagnosed 
1976-2013, resident in Switzerland or abroad, diagnosed 
or treated in Switzerland (N=8957). 
Up to 31st December 2013, a total of 8957 cases classiﬁ-
able according to the ICCC-3, or Langerhans cell histiocyto-
ses (LCH), have been registered in the SCCR. These tumours 
were diagnosed in 8846 patients. Among these, 8735 pa-
tients had only one primary neoplasm, 110 patients had 
two primary neoplasms and 2 patients had three primary 
neoplasms at age 0-20 years. 
The SCCR started in 1976. Initially, only patients aged 
0 to 15 years who participating in clinical trials were reg-
istered. Non-trial patients have been included since 1981, 
resulting in a signiﬁcant increase in the number registered. 
In the early 1990s, the introduction of the ﬁrst electronic 
database further increased case registration. Since then, an-
nual registration has remained constant (Figure 1).
In the last ﬁve years (2009-2013), a total of 1284 newly 
diagnosed cases were registered; among them 1144 cases 
in Swiss residents (Table 1).
Swiss residents account for 7947 (89%) of all cases and 
foreign residents for 1010 (11%) cases (Table 2). Foreign 
residents make up 40% (156/239) of all retinoblastoma pa-
tients. This is due to the international reputation of the Jules 
Gonin Hospital in Lausanne, which is the national centre for 
retinoblastoma treatment but also attracts many patients 
from abroad.
3. Routine Analyses
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Figure 1
Annual number of registered cases 
over time
Swiss and foreign residents, age at 
diagnosis 0-14 years; period of 
diagnosis 1976-2013; all diagnoses 
(ICCC-3 or Langerhans cell histio-
cytosis); N=7216
14
 
  Age at diagnosis (years)
 All ages (0-20) Children (0-14) Adolescents (15-20)
Country of residence n % n % n %
Switzerland 7947 88,7 6371 88,3 1576 90,5
Foreign countries 1010 11,3 845 11,7 165 9,5
Europe  685 7,6 588 8,1 97 5,6
 • Neighbouring countries 394 4,4 335 4,6 59 3,4
 - Austria 12 0,1 11 0,2 1 0,1
 - France 133 1,5 101 1,4 32 1,89
 - Germany 78 0,9 73 1,0 5 0,3
 - Italy  170 1,9 149 2,1 21 1,2
 - Liechtenstein 1 0,0 1 0,0 0 0,0
 • Other European countries 291 3,2 253 3,5 38 2,2
Middle East 32 0,4 26 0,4 6 0,3
North Africa 156 1,7 124 1,7 32 1,8
Other African countries 49 0,5 41 0,6 8 0,5
All other countries 55 0,6 47 0,7 8 0,5
Abroad  33 0,4 19 0,3 14 0,9
TOTAL  8957 100%  7216 100%  1741 100%
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2013; all diagnoses (ICCC-3 or 
Langerhans cell histiocytoses); N=8957
Table 2 
Total number of cases registered
 in the SCCR, by country 
of residence
Table 1
Total number of 
cases registered in the 
SCCR, by period of 
diagnosis
   All patients Swiss residents Foreign  
   residents
   Age at Age at Age at 
   diagnosis diagnosis diagnosis  
 Year of diagnosis (years) (years) (years)
   0-14 15-20 0-14 15-20 0-14 15-20
 1976 - 1983 995 227 870 204 125 23
 1984 - 1988 862 229 737 207 125 22
 1989 - 1993 1015 240 868 210 147 30
 1994 - 1998 1057 297 940 264 117 33
 1999 - 2003 1075 268 995 241 80 27
 2004 - 2008 1082 326 966 301 116 25
 2009 - 2013 1130 154 995 149 135 5
    7216 1741  6371 1576  845 165
Swiss and foreign residents, age at diagnosis 0-20 years; period of diagnosis 1976-2013; all diagnoses (ICCC-3 or 
Langerhans cell histiocytoses); N=8957
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3.3 Swiss residents aged 0-14 years 
 at diagnosis (N=6371)
This chapter reports on cases aged 0-14 years and 
resident in Switzerland at diagnosis with a tumour coded 
according to ICCC-3 or a Langerhans cell histiocytoses. Re-
sults for this age group can be compared directly to data 
from other countries. 
Diagnoses
The International Classiﬁcation of Childhood Cancer 
(ICCC-3) distinguishes 12 groups of cancers (Table 3). The 
most commons are leukaemias (33% of all cancers), fol-
lowed by tumours of the central nervous system (20%; 
especially brain tumours); and lymphomas (12%). Other 
cancers arise from embryonic tissue. These include neu-
roblastoma (7%) from primitive neural tissue, nephroblas-
toma (5%) from renal tissue, hepatoblastoma (1%) in the 
liver, germ cell tumours (3%), and retinoblastoma (2%). 
Germ cell tumours may arise in the gonads (ovaries 
and testes), or in other sites, such as the brain (intracranial 
germ cell tumours). Soft tissue sarcomas (7%), and malig-
nant bone tumours (4%) arise from abnormal connective 
tissue. Occasionally, children also develop carcinomas such 
as melanomas or other rare tumours (3%). Langerhans cell 
histiocytosis (3%) is ofﬁcially not counted as a malignant 
disease. But as children with this disease are treated sim-
ilarly to those with cancer and in rare cases also die, they 
are recorded in the Swiss Childhood Cancer Registry. The 
relative frequency of the different tumour types varies with 
age (Table 3 and Figure 2). 
 All children By age at diagnosis (years)
  <1 1-4 5-9 10-14
Diagnosis n % n % n % n % n %
I Leukaemias, myeoloproliferative  
 diseases and myelodysplastic diseases  2103 33,0 83 13,3 1006 45,0 592 34,6 422 23,4
II Lymphomas and reticuloendothelial neoplasms 790 12,4 19 3,0 127 5,7 224 13,1 420 23,3
III Central nervous system neoplasms   1247 19,6 68 10,9 360 16,1 463 27,1 356 19,8
IV Neuroblastoma and other peripheral 
 nervous cell tumours    421 6,6 183 29,2 187 8,4 33 1,9 18 1,0
V Retinoblastoma     155 2,4 70 11,2 75 3,4 8 0,5 2 0,1
VI Renal tumours     327 5,1 46 7,3 190 8,5 79 4,6 12 0,7
VII Hepatic tumours     61 1,0 21 3,4 24 1,1 7 0,4 9 0,5
VIII Malignant bone tumours    277 4,3 0 0,0 19 0,9 82 4,8 176 9,8
IX Soft tissue and other extraosseous sarcomas  426 6,7 48 7,7 122 5,5 104 6,1 152 8,4
X Germ cell tumours, trophoblastic tumours  
 and neoplasms of gonads    175 2,7 35 5,6 41 1,8 24 1,4 75 4,2
XI Other malignant epithelial neoplasms 
 and malignant melanomas    167 2,6 10 1,6 9 0,4 38 2,2 110 6,1
XII Other speciﬁed and 
 unspeciﬁed malignant neoplasms   16 0,3 3 0,5 5 0,2 1 0,1 7 0,4
 Langerhans cell histiocytosis    206 3,2 40 6,4 69 3,1 56 3,3 41 2,3
 Total      6371 100% 626 100% 2234 100% 1711 100% 1800 100%
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2013; all diagnoses (ICCC-3 or langerhans cell histiocytosis) ; N=6371 
Table 3 Main diagnostic groups according to ICCC-3, by age at diagnosis
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Figure 2 
Main diagnostic groups according to ICCC-3, by age at diagnosis
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III.  CNS neoplasms
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V.  Retinoblastoma
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VII. Hepatic tumours
VIII. Malignant bone tumours
IX.  Soft tissue sarcomas
X. Germ cell tumours
XI.  Other malignant 
 epithelial neoplasms
XII.  Other speciﬁed and 
 unspeciﬁed malignant 
 neoplasms 
Langerhans cell histiocytosis
Follow-up information
The SCCR collects follow-up information for patients in sev-
eral ways: 
1. Clinical follow-up is any contact the patient has with 
the paediatric oncology and haematology centre. An-
nual clinical follow-up care in paediatric centres usually 
ends 5-10 years after diagnosis. Then the patient is 
ofﬁcially discharged or referred to an adult oncology 
centre. Alternatively clinical follow-up also ends, as 
soon as the patient dies. 
2. Long-term epidemiological follow-up for vital sta-
tus, subsequent neoplasms and current health employs 
four complementary approaches:
• Vital status and current address are updated 
by contacting municipal population registers. Vital 
status is known for most cases: among the 6371 
patients, 1577 (25%) have died, and 4794 (75%) 
are still alive (Table 4). Among these, most (4338) 
have been followed-up during the past 5 years, 314 
(7%) have last been followed up between 2004 and 
2008, and only 142 (3%) before 2004. Among the 
latter, 92 are lost to follow-up, because they moved 
abroad. 
• Causes of death are retrieved from Swiss mortality 
statistics by record linkage.
• Second primary neoplasms are notiﬁed via paedi-
atric oncology and haematology centres, detected by 
regular comparison with cantonal (regional) cancer 
registries in Switzerland, or self-reported by survivors 
and then validated with pathology reports.
• Morbidity and quality of life are assessed by 
paper questionnaires to survivors in the Swiss Child-
hood Cancer Survivor Study and Childhood Cancer 
Follow-up Study (SCCSS & CCFU, Chapter 4).
Table 4 Follow-up information available in the SCCR
    n %
Alive Total 4794 75%
 Last follow-up after 2008 4338 
 Last follow-up 2004-2008 314 
 Last follow-up before 2004 142 
Deceased  1577 25%
Total  6371 100%
Swiss residents; age at diagnosis 0-14 years; period of diagnosis 1976-2013; all 
diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=6371 
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Figure 3 
Survival of patients in the SCCR, 
by period of diagnosis
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1976-2013; all diagnoses 
(ICCC-3 or Langerhans cell histiocytoses); 
N=6371; adjusted for sex, age at diagnosis 
and ICCC-3 groups
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Figure 4 
Survival of patients by diagnostic 
groups according to ICCC-3
Swiss residents; age at diagnosis 0-14 years; 
period of diagnosis 1994-2013 all diagnoses 
(ICCC-3 or Langerhans cell histiocytoses);
 N=3896; adjusted for sex and age at diagnosis
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Survival
Long-term survival has improved signiﬁcantly over the 
last decades (Figure 3).
Ten-year survival increased from 61% in children diag-
nosed between 1976 and 1983, to 70% in children diag-
nosed between 1984-1993, 77% in children diagnosed 
between 1994 and 2003, and 83% in children diagnosed 
within the last decade (2004-2013). 
Survival varied widely between diagnostic groups. Figure
4 presents survival by diagnostic group according to ICCC-3 
in children diagnosed between 1994 and 2013. Of 3896, 
756 (19%) have died. The following numbers describe ﬁve-
year survival for each main diagnostic group: 100% for 
Langerhans cell histiocytoses; 96% for germ cell tumours; 
92% for lymphoma; 91% for renal tumours; 96% for ret-
inoblastoma; 86% for malignant bone tumours; 83% for 
children with leukaemia; 74% for soft tissue sarcomas; 72% 
for central nervous system neoplasms; 66% for hepatic 
tumours and 63% for neuroblastoma.
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Cancer incidence (2004-2013) in Switzerland, for 
children aged 0-14 years at diagnosis
Table 5 describes the tumours registered in the SCCR 
during the last ten years (2004-2013). Diagnoses are coded 
according to ICCC-3, most tumours were more common 
in boys than in girls, with the exception of neuroblastoma, 
retinoblastoma, nephroblastoma, germ cell tumours, and 
other malignant epithelial neoplasms including malignant 
melanomas.
The age-standardised incidence (according to the Eu-
ropean standard population) of any childhood cancer 
(not including Langerhans cell histiocytoses) was 15.9 per 
100,000 person-years. Incidence was highest among chil-
dren aged less than 1 year with 23.4 cases per 100,000 
person-years (boys 22.5, girls 24.4). Incidence was lowest 
in 9 year olds with 9.1 cases per 100,000 person-years 
(boys 9.3, girls 8.8) (Figure 5 shows crude incidence rates 
in Swiss residents; age at diagnosis 0-14 years; period of 
diagnosis 1994-2013; all diagnoses (ICCC-3 but not includ-
ing Langerhans cell histiocytosis); N=3757, Figure 6 shows 
age- and sex-speciﬁc incidence rates for age 0-14).
   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 645 33,9 1,5 4,9 5,4
 a. Lymphoid leukaemias 519 80,5 1,5 4,6 4,4
 b. Acute myeloid leukaemias 80 12,4 1,9 6,3 0,7
 c. Chronic myeloproliferative diseases 7 1,1 6,0 10,0 0,1
 d. Myelodysplastic syndrome and other myeloproliferative diseases 31 4,8 2,9 7,0 0,3
 e. Unspeciﬁed and other speciﬁed leukaemias 8 1,2 0,6 4,6 0,1
II Lymphomas and reticuloendothelial neoplasms 216 11,4 1,7 10,7 1,8
 a. Hodgkin lymphomas 95 44,0 0,8 12,7 0,8
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 62 28,7 2,6 9,0 0,5
 c. Burkitt lymphoma 53 24,5 6,6 6,9 0,4
 d. Miscellaneous lymphoreticular neoplasms 6 2,8 0,5 1,1 0,1
 e. Unspeciﬁed lymphomas 0 NA NA NA NA
III CNS and miscellaneous intracranial and intraspinal neoplasms 417 21,9 1,1 7,0 3,5
 a. Ependymomas and choroid plexus tumour 40 9,6 1,2 2,7 0,3
 b. Astrocytomas 169 40,5 1,2 7,2 1,4
 c. Intracranial and intraspinal embryonal tumours 83 19,9 1,4 6,5 0,7
 d. Other gliomas 51 12,2 1,0 6,5 0,4
 e. Other speciﬁed intracranial and intraspinal neoplasms 64 15,3 0,9 11,6 0,5
 f. Unspeciﬁed intracranial and intraspinal neoplasms 10 2,4 1,5 7,8 0,1
IV Neuroblastoma and other peripheral nervous cell tumours 120 6,3 1,0 1,3 1,0
 a. Neuroblastoma and ganglioneuroblastoma 120 100,0 1,0 1,3 1,0
 b. Other peripheral nervous cell tumours 0 NA NA NA NA
V Retinoblastoma 36 1,9 0,6 1,1 0,3
VI Renal tumours 95 5,0 0,9 3,4 0,8
 a. Nephroblastoma and other nonepithelial renal tumours 90 94,7 0,9 3,2 0,8
 b. Renal carcinomas 5 5,3 0,7 12,8 0,0
 c. Unspeciﬁed malignant renal tumours 0 NA NA NA NA
VII Hepatic tumours 17 0,9 2,4 1,6 0,1
 a. Hepatoblastoma 15 88,2 2,0 1,6 0,1
 b. Hepatic carcinomas 2 11,8 7,0 0,0 0,0
 c. Unspeciﬁed malignant hepatic tumours 0 NA NA NA NA
Table 5 – Childhood cancer diagnosed in Switzerland 2004-2013: number of cases, relative frequency, sex ratio, median age at diag-
nosis and incidence standardised according to the European standard population, by diagnostic groups according to ICCC-3
Swiss residents; age at diagnosis 0-14 years, period of diagnosis 2004-2013, all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=1961
* Incidence: newly diagnosed tumours in a one year time period per 100,000 persons (person-years) 
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   Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median) Incidence*
VIII Malignant bone tumours 82 4,3 1,1 11,0 0,7
 a. Osteosarcomas 39 47,6 0,9 11,2 0,3
 b. Chondrosarcomas 0 NA NA NA NA
 c. Ewing tumour and related sarcomas of bone 42 51,2 1,3 10,6 0,4
 d. Other speciﬁed malignant bone tumours 0 NA NA NA NA
 e. Unspeciﬁed malignant bone tumours 1 1,2 0,0 14,7 0,0
IX Soft tissue and other extraosseous sarcomas 144 7,6 1,3 7,5 1,2
 a. Rhabdomyosarcomas 78 54,2 1,3 5,3 0,7
 b. Fibrosarcomas, peripheral nerve sheath tumours, and other ﬁbrous neoplasms 10 6,9 2,3 10,9 0,1
 c. Kaposi sarcoma 0 NA NA NA NA
 d. Other speciﬁed soft tissue sarcomas 44 30,6 1,1 11,1 0,4
 e. Unspeciﬁed soft tissue sarcomas 12 8,3 2,0 0,8 0,1
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 58 3,1 1,2 6,9 0,5
 a. Intracranial and intraspinal germ cell tumours 14 24,1 1,8 12,2 0,1
 b. Malignant extracranial and extragonadal germ cell tumours 15 25,9 0,9 0,1 0,1
 c. Malignant gonadal germ cell tumours 27 46,6 1,3 11,4 0,2
 d. Gonadal carcinomas 0 NA NA NA NA
 e. Other and unspeciﬁed malignant gonadal tumour 1 1,7 0,8 0,0 0,0
XI Other malignant epithelial neoplasms and malignant melanomas 65 3,4 0,8 12,0 0,5
 a. Adrenocortical carcinomas 3 4,6 2,0 1,7 0,0
 b. Thyroid carcinomas 13 20,0 0,3 13,4 0,1
 c. Nasopharyngeal carcinomas 1 1,5 0,0 12,2 0,0
 d. Malignant melanomas 18 27,7 1,3 11,0 0,2
 e. Skin carcinomas 8 12,3 1,7 6,3 0,1
 f. Other and unspeciﬁed carcinoma 22 33,8 0,6 12,0 0,2
XII Other and unspeciﬁed malignant neoplasms 5 0,3 0,7 0,4 0,0
 a. Other speciﬁed malignant tumours 2 40,0 1,0 1,8 0,0
 b. Other unspeciﬁed malignant tumours 3 60,0 0,5 0,4 0,0
Total (not including Langerhans cell histiocytosis) 1900 100,0 1,3 6,1 15,9
 Langerhans cell histiocytosis 61 3,1 1,1 5,2 0,5
Total (including Langerhans cell histiocytosis) 1961 100,0 1,3 6,1 16,4
 
* Incidence: newly diagnosed tumours in a one year time period per 100,000 persons (person-years); NA: not applicable
Table 5 Continued
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3.4 Swiss residents aged 15-20 years at diagnosis  
 (N=450)
Table 6 describes the tumours registered in the last ten 
 years (2004-2013) diagnosed in adolescent patients 
(aged 15-20 years at diagnosis, N=450). Because data on 
adolescents are currently not complete within the SCCR, we 
do not present incidence rates. In adolescents the sex ratio 
is closer to 1 than in those aged 0-14 years at diagnosis. 
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases  58 12,9 1,9 16,1
 a. Lymphoid leukaemias  34 58,6 2,1 16,0
 b. Acute myeloid leukaemias  16 27,6 1,3 16,2
 c. Chronic myeloproliferative diseases  4 6,9 3,0 18,1
 d. Myelodysplastic syndrome and other myeloproliferative diseases  4 6,9 3,0 16,7
 e. Unspeciﬁed and other speciﬁed leukaemias  0 NA NA NA
II Lymphomas and reticuloendothelial neoplasms  116 25,9 0,8 16,7
 a. Hodgkin lymphomas  79 68,1 0,8 16,6
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma)  32 27,6 0,8 17,0
 c. Burkitt lymphoma  4 3,4 1,0 18,4
 d. Miscellaneous lymphoreticular neoplasms  1 0,9 0,0 16,6
 e. Unspeciﬁed lymphomas  0 NA NA NA
III CNS and miscellaneous intracranial and intraspinal neoplasms  80 17,9 1,0 16,4
 a. Ependymomas and choroid plexus tumour  5 6,3 0,3 18,0
 b. Astrocytomas  28 35,0 0,6 16,4
 c. Intracranial and intraspinal embryonal tumours  16 20,0 1,3 16,1
 d. Other gliomas  9 11,3 2,0 16,8
 e. Other speciﬁed intracranial and intraspinal neoplasms  22 27,5 1,2 16,3
 f. Unspeciﬁed intracranial and intraspinal neoplasms  0 NA NA NA
IV Neuroblastoma and other peripheral nervous cell tumours  0 NA NA NA
 a. Neuroblastoma and ganglioneuroblastoma  0 NA NA NA
 b. Other peripheral nervous cell tumours  0 NA NA NA
V Retinoblastoma  0 NA NA NA
VI Renal tumours  7 1,6 2,5 16,6
 a. Nephroblastoma and other nonepithelial renal tumours  2 28,6 4,5 16,0
 b. Renal carcinomas  5 71,4 1,5 17,4
 c. Unspeciﬁed malignant renal tumours  0 NA NA NA
VII Hepatic tumours  4 0,9 3,0 16,0
 a. Hepatoblastoma  0 NA NA NA
 b. Hepatic carcinomas  4 100,0 3,0 16,0
 c. Unspeciﬁed malignant hepatic tumours  0 NA NA NA
VIII Malignant bone tumours  48 10,7 1,5 16,3
 a. Osteosarcomas  35 72,9 1,7 16,5
 b. Chondrosarcomas  1 2,1 0,0 15,1
 c. Ewing tumour and related sarcomas of bone  10 20,8 1,0 16,0
 d. Other speciﬁed malignant bone tumours  2 4,2 1,0 16,7
 e. Unspeciﬁed malignant bone tumours  0 NA NA NA
Table 6 – Adolescent cancer diagnosed in Switzerland 2004-20013: number of cases, relative frequency, sex ratio and median age at 
diagnosis 
Age at diagnosis 15-20 years, period of diagnosis 2004-2013, all diagnoses (ICCC-3 or Langerhans cell histiocytosis); N=450  
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Table 6 Continued
    Relative Sex ratio Age at Dx 
 Diagnosis n frequency (male:female) (Median)
IX Soft tissue and other extraosseous sarcomas  31 6,9 0,9 16,5
 a. Rhabdomyosarcomas  13 41,9 0,9 15,9
 b. Fibrosarcomas, peripheral nerve sheath tumours, and other ﬁbrous neoplasms  3 9,7 0,5 15,8
 c. Kaposi sarcoma  0 NA NA NA
 d. Other speciﬁed soft tissue sarcomas  11 35,5 0,4 17,0
 e. Unspeciﬁed soft tissue sarcomas  4 12,9 3,0 16,6
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads  32 7,1 9,7 17,8
 a. Intracranial and intraspinal germ cell tumours  3 9,4 0,0 17,2
 b. Malignant extracranial and extragonadal germ cell tumours  0 NA NA NA
 c. Malignant gonadal germ cell tumours  27 84,4 26,0 18,0
 d. Gonadal carcinomas  2 6,3 0,0 15,7
 e. Other and unspeciﬁed malignant gonadal tumour  0 NA 0,0 NA
XI Other malignant epithelial neoplasms and malignant melanomas  71 15,8 0,7 18,2
 a. Adrenocortical carcinomas  1 1,4 0,0 17,0
 b. Thyroid carcinomas  22 31,0 0,2 17,6
 c. Nasopharyngeal carcinomas  3 4,2 0,0 17,9
 d. Malignant melanomas  28 39,4 0,8 18,5
 e. Skin carcinomas  5 7,0 0,0 18,6
 f. Other and unspeciﬁed carcinoma  12 16,9 5,0 17,9
XII Other and unspeciﬁed malignant neoplasms  1 0,2 0,0 15,2
 a. Other speciﬁed malignant tumours  1 100,0 0,0 15,2
 b. Other unspeciﬁed malignant tumours  0 NA NA NA
 Total (not including Langerhans cell histiocytosis)  448 100,0 1,1 16,8
 Langerhans cell histiocytosis  2 0,4 1,0 16,2
 Total (including Langerhans cell histiocytosis)  450 100,0 1,1 16,8
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4. Research projects on childhood cancer
Current research projects of the childhood cancer reg-
istry are summarised in Table 7. All projects are described 
in more detail in the remainder of Chapter 4. Additional 
information is available from the references and from the 
investigators. Further, we thank the supporters for their 
generous contributions towards the research projects.
Table 7
Current research projects of the SCCR, summary
since 01.2006
08.2012-08.2014
02.2011-01.2016
11.2013-10.2018
since 2010
08.2012-08.2015
since 2012
since 2013
04.2011-04.2014
06.2010-02.2013
03.2013-11.2013
01.2013-12.2014
09.2013-08.2016
Von der Weid NX, 
Kuehni CE
Kuehni CE
Kuehni CE
Kuehni CE, Bergstraesser E
Kuehni CE, Angst R
Michel G
Kuehni CE
Kuehni CE
Kuehni CE
Mullis P
Mullis P, Kuehni CE
Kuehni CE
Kuehni CE
Michel G
Michel G
Michel G
Kuehni CE
Spycher BD
Spycher BD
Spycher BD
Swiss Cancer League 
(KLS-2215-02-2008)
Kinderkrebshilfe Schweiz
Cancer League Bern 
Cancer League Zurich 
Cancer League Aarau
Swiss National Science Foundation 
(PZ00P3_121682/1)
EU FP7 PanCareSurfUp 
(HEALTH-F2-2010-257505)
Swiss Cancer League 
(KFS - 02783-02-2011)
EU FP7 PanCareLife 
(HEALTH-F2-2013-602030) 
Swiss Cancer League 
(KFS - 3412-02-2014)
EU FP 7 (HEALTH-F2-2009-223497)
Swiss Cancer League
(KLS - 2948-02-2012)
Swiss National Science Foundation
Swiss Bridge
Kinderkrebshilfe Schweiz
Swiss National Science Foundation 
(100019_153268 / 1) 
Kinderkrebshilfe Schweiz
Swiss Cancer League 
(KFS - 02631-08-2010)
Federal Ofﬁce of Public Health
Federal Ofﬁce of Public Health
Swiss Cancer League 
(KFS-3049-08-2012)
Swiss National Science Foundation 
Project name Senior investigator Funding sources Study period
 Outcome research 
 1 Swiss Childhood Cancer Survivor Study  
  (SCCSS)
 
 
 
 
 2 Follow-up care after childhood and young  
  adult cancer (CCFU)
 3 PanCare childhood and adolescent cancer 
  survivor care and follow-up studies 
  (PanCareSurFup)
 
 4 PanCare Studies in Fertility and Ototoxicity to  
  improve Quality of Life after Cancer during  
  Childhood, Adolescence and Young 
  Adulthood (PanCareLIFE)
 
 5 Risk of cancer and long-term mortality in 
  children treated with growth hormone: 
  Swiss  participation in the EU FP7 project (SAGhE) 
 6 Mortality after cancer in childhood and 
  adolescence 
 7 Fertility after Chemo- and Radiotherapy in 
  Childhood and Adolescence, FeCt – Multicentre
 8 Parents of long-term childhood cancer survivors
 9 Effectiveness of transition from paediatric to
  adult care after childhood cancer
Aetiology of childhood cancer 
 10 Childhood cancer and vicinity of residence  
  to petrol stations and roads: census-based  
  nation wide cohort study (PETROL)
11 Childhood cancer and geographically deﬁned
  exposures in Switzerland: a census-based 
  nationwide cohort study
 12 The role of population mixing and exposure  
  to infections in the aetiology of childhood 
  leukaemia: a national cohort study
 13 The spatial epidemiology of childhood cancer  
  in Switzerland
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4.1 Swiss Childhood Cancer Survivor Study   
 (SCCSS)
 Background: Thanks to therapeutic improvements in 
the past decades, survival rates for childhood cancer now 
exceed 80%, leading to a growing population of long-
term survivors. However, cancer and cancer treatments 
lead to adverse late effects and the health and quality of 
life of survivors are of increasing concern. In Switzerland 
and other countries, comprehensive data on the burden of 
late effects of childhood cancer and its risk factors, as well 
as data on the use of follow-up care in long-term survivors 
is scarce.
 Objectives: The project investigates long-term out-
comes of survivors of childhood and adolescent cancer. It 
studies the incidence and spectrum of various somatic and 
psycho-social outcomes including late mortality, second pri-
mary malignancies, somatic health and medication, mental 
health, educational achievements, health related quality of 
life, and their association with a number of risk factors (tu-
mour, treatment modalities, demographic characteristics). 
Current practices of health-care provision and health be-
haviour in long-term survivors are also investigated.
 Methods: Prospective cohort study based on the pop-
ulation of children and adolescents registered in the SCCR. 
Eligible for the study are all individuals, who have been di-
agnosed with cancer at age <21 years, who are 5-year sur-
vivors and still alive, and who were Swiss residents at time 
of diagnosis. A detailed questionnaire is sent to all partic-
ipants. Questionnaire data are complemented with phone 
interviews to patients and validated with information from 
general practitioners and hospital records. For comparison, 
the same questionnaire is sent to siblings of childhood can-
cer survivors.
 Rationale and signiﬁcance: The existing database of 
the SCCR provides the rare opportunity for a nationwide 
study on long-term outcomes in survivors of childhood can-
cer. The project will increase the knowledge on the inci-
dence of, and risk factors for late effects, and provide a 
summary of the current status of care in Switzerland. As 
many late effects can be prevented or cured if diagnosed 
early, this study will contribute to improving the health of 
current and future survivors of childhood cancer.
 Current status of the project: Among 2930 eligible 
survivors aged 0-<16 years at diagnosis, 2235 (76%) com-
pleted the questionnaire. Among 598 contacted survivors 
aged 16-20 years at diagnosis, 320 (54%) replied. Of 1522 
contacted siblings 866 (57%) participated. The study is on-
going and new 5 year survivors are included at regular in-
tervals. Data are continuously analysed and published.
 Study team: Kuehni CE, von der Weid NX, Michel G, 
Kasteler R, Sommer G, Wengenroth L, Weiss A. Institute of 
Social and Preventive Medicine, University of Bern; 
 Funding: Swiss Cancer League (Grant No KLS-01605-
10-2004, KLS-2215-02-2008 and KLS-3412-02-2014), Ber-
nese Cancer League, Cancer League Zurich, Cancer League 
Aargau.
 Contact: Claudia Kuehni (claudia.kuehni@ispm.unibe.ch), 
Grit Sommer (grit.sommer@ispm.unibe.ch)
 Publications (for details see publication list on page 33):
- Wengenroth L. et al. Pediatr Blood Cancer. 2014
- Gianinazzi ME. et al. Care Cancer. 2014
- Gianinazzi ME. et al. Pediatr Blood Cancer. 2014
- Gianinazzi ME. et al. Psychooncology. 2013
- Rueegg CS. et al. Pediatr Blood Cancer. 2013
- Rueegg CS. et al. J Cancer Surviv. 2013
 - Rebholz CE. et al. Pediatr Blood Cancer. 2012
- Kuehni CE. et al. Cancer. 2012
- Rebholz CE. et al. Br J Cancer. 2012
- Kuehni CE. et al. Int J Epidemiol. 2012
- Rueegg CS. et al. PLoS One. 2012
- Essig S. et al. PLoS One. 2012 
- Rebholz CE. et al. Eur J Cancer. 2011
- Michel G. et al. Psycho-Oncology. 2011
- Michel G. et al. Journal of Clinical Oncology. 2011
- Marquis A. et al. Pediatr Blood Cancer. 2010
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4.2 Follow-up Care After Childhood and   
 Young Adult Cancer (CCFU)
 Background: Treatment for cancer in children and 
young adults has greatly improved and most patients are 
being cured today. However, more than 50% of survivors 
of childhood cancer suffer from late-effects. To detect and 
treat late-effects as early as possible, many survivors should 
continue to attend follow-up care long after their cancer 
has been cured. Various models of follow-up care have 
been described, but so far none has been implemented in 
Switzerland. While follow-up care needs to be constantly 
updated to meet the current status of research, survivor 
participation is only ensured if follow-up is convenient.
 Objectives: 1) To compare the advantages and disad-
vantages of follow-up care models currently used in Europe; 
2) To determine the current availability and use of follow-up 
care in survivors of childhood and young adult cancers in 
Switzerland; and, 3) To determine the advantages and dis-
advantages of follow-up care models as perceived by survi-
vors, oncologists and family practitioners, and to compare 
their views and opinions.
 Methods: For part 1), we invited 198 clinics and fol-
low-up programmes in Europe to complete a questionnaire 
survey describing the follow-up care available at their insti-
tution. For part 2), we analysed the current use of follow-up 
care together with the psychological well-being in child-
hood cancer survivors, using data from the Swiss Childhood 
Cancer Survivor Study (SCCSS). In part 3), a questionnaire 
survey assessed opinions and perspectives on both currently 
used and desired optimal follow-up care. The sample in-
cluded childhood, adolescent and young adult cancer sur-
vivors diagnosed with cancer between 1990 and 2005 and 
aged <25 years, who survived for >5 years and who were 
aged 18+ years at the time of the study. In addition, parents 
of survivors aged 11-18 years, paediatric and adult oncolo-
gists and haematologists and family practitioners have com-
pleted a questionnaire.
 Rationale and signiﬁcance: This project provides an 
overview of follow-up care in Europe and will describe 
survivor, oncologist and family practitioner preferences for 
follow-up care models in Switzerland. We will determine 
the differences between the three groups in order to im-
prove follow-up care and adapt it to differing preferences. 
The project will provide the basis for the development of a 
standardised model of follow-up care for childhood cancer 
survivors in Switzerland.
 Current status of the project: All questionnaire sur-
veys have been completed, and several papers have been 
published.
 Study team: Michel G, Rueegg CS, Department of 
Health Sciences and Health Policy, University of Lucerne; 
Kuehni CE, Institute of Social and Preventive Medicine, Uni-
versity of Bern
 Funding: Swiss National Science Foundation Ambizione 
Grant to Michel G (PZ00P3_121682 and PZ00P3_141722)
 Contact: Gisela Michel (gisela.michel@unilu.ch)
 Publications (for details see publication list on page 33): 
- Lupatsch J. et al. JAYAO. 2014
- Vetsch J. et al. Pediatr Blood Cancer. 2014
- Gianinazzi ME. et al. Support Care Cancer. 2014
- Gianinazzi ME. et al. Pediatr Blood Cancer. 2014
- Singer S. et al. Pediatr Blood Cancer. 2013
- Gianinazzi ME. et al. Psychooncology. 2013
- Essig S. et al. PLoS ONE. 2012
- Michel G. et al. Psychooncology. 2011
- Rebholz C. et al. Eur J Cancer. 2011
- Michel G. et al. Journal of Clinical Oncology. 2010
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4.3 PanCare Childhood and Adolescent 
 Cancer Survivor Care and Follow-Up 
 Studies (PanCareSurFup)
 Background: Long-term survival after childhood cancer 
exceeds 80%, but two thirds of survivors develop chron-
ic conditions. Late mortality is increased as a consequence 
of the cancer and its treatment. More than ten years after 
diagnosis, deaths from second primary cancers and circula-
tory causes predominate. There is a need to identify avoid-
able risk factors for these late effects. These risk factors are 
being investigated within the international study PanCar-
eSurFup, where Switzerland is one of the 11 participating 
European countries. 
 Objectives: The study investigates incidence and risk 
factors for second primary cancers, cardiovascular diseases 
and late mortality. Furthermore, guidelines for the clinical 
follow-up of survivors will be developed. 
 Methods: The Swiss cohort of 5-year survivors of child-
hood cancer will contribute to the pan-European cohort. 
Within the cohort we identify cardiovascular diseases and 
second primary cancers via: a) questionnaires; b) mortality 
records; and, c) record linkage with cantonal cancer regis-
tries (for second primary cancers). Patient-reported diseases 
are validated with medical records. Survivors suffering from 
severe cardiovascular diseases or second primary sarcomas 
or carcinomas are included in a nested case-control study. 
For those patients, we are extracting details of radio- and 
chemotherapy from medical records. In close collaboration 
with experts from across Europe, we write systematic re-
views to develop evidence-based, standardised guidelines 
for clinical follow-up of survivors. 
 Rationale and signiﬁcance: This research project pro-
vides a unique opportunity to study the most severe and life 
threatening late effects of childhood cancer in an interna-
tional setting that maximises statistical power and general-
isability of results. The identiﬁcation of avoidable causes for 
cardiovascular diseases and second primary cancers will al-
low treatments to be adapted for new patients. The goal is 
to maximize cure rates with minimal long-term side effects. 
 Current status of project: The Swiss cohort dataset 
includes 4719 5-year survivors. Data on vital status, caus-
es of death, as well as data on second primary neoplasms 
and cardiovascular diseases are currently being analysed. 
The case-control studies are ongoing and we are currently 
collecting detailed treatment data from medical records for 
survivors included in these studies.
 Study team: Kuehni CE, Kuonen R, Sommer G, Schindler 
M, Institute of Social and Preventive Medicine, University of Bern; 
Michel G, Department of Health Sciences and Health Policy, 
University of Lucerne
 Funding: European Union FP7- HEALTH 2010.2.4.1-7 
(Project No. 257505). Swiss Cancer League (Grant No KFS-
02783-02-2011) 
 Contact: Claudia Kuehni (claudia.kuehni@ispm.unibe.ch), 
Rahel Kuonen (rahel.kuonen@ispm.unibe.ch)
 Publications (for details see publication list on page 33): 
Brown M. et al. Pediatr Blood Cancer. 2014
Feijen. et al. PloS one. 2014
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4.4 PanCare Studies in Fertility and Ototoxicity 
 to Improve Quality of Life after Cancer 
 during Childhood, Adolescence and 
 Young Adulthood (PanCareLIFE)
 Background: Improved therapies and care have in-
creased survival rates of childhood cancer in recent de-
cades. This results in an increasing population of childhood 
cancer survivors. However, cancer treatments are harsh and 
can cause serious side-effects, such as hearing loss or infer-
tility, which can greatly impact survivors’ quality of life in the 
long term. PanCareLIFE is a large international study, which 
identiﬁes individual risk factors for these late effects. 
 Objectives: The study investigates incidence, severity 
and the risk factors for hearing loss and infertility in child-
hood cancer survivors. Furthermore, it compares health-re-
lated quality of life and its determinants between countries. 
 Methods: The Swiss cohort of 5-year survivors of child-
hood cancer will be part of the pan-European cohort look-
ing at health related quality of life, hearing loss and infertil-
ity. Within this cohort we will identify patients with hearing 
loss or infertility via a questionnaire. Patients with hearing 
loss will then be included into a nested case-control study 
to identify non-genetic and genetic risk factors. Patient-re-
ported diseases will be validated via the collection of audio-
grams from original medical records and detailed treatment 
data will be collected for selected patients. 
 Rationale and signiﬁcance: This large pan-Europe-
an cohort provides a unique opportunity to study late ef-
fects such as hearing loss, infertility and their impact on 
health-related quality of life. The ﬁndings of this project will 
lead to improvements in patient care. 
 Current status of project: The study started in No-
vember 2013. Detailed study protocols and questionnaires 
for the different study aims are currently being developed.
 Study team: Kuehni CE, Kuonen R, Sommer G, Kastel-
er R, Weiss A, Institute of Social and Preventive Medicine, 
University of Bern; von der Weid NX, Paediatric Oncology, 
University Children’s Hospital Basel
 Funding: European Union FP7-HEALTH-2013-INNOVA-
TION-1 HEALTH.2013.2.4.1-3 (Project No. 602030), Swiss 
Cancer League (Grant No KFS-3412-02-2014) 
 Contact: Claudia Kuehni (claudia.kuehni@ispm.unibe.ch), 
Rahel Kuonen (rahel.kuonen@ispm.unibe.ch)
4.5 Risk of Cancer and Long-Term Mortality in 
 Children Treated with Growth Hormone: 
 Swiss Participation in the EU FP7 Project 
 (SAGhE) 
 Background: Growth Hormone (GH) promotes body 
growth. If GH production is impaired, it can be substituted 
with daily injections. Growth hormone deﬁciency (GHD) is 
the most common endocrine late effect of childhood can-
cer treatment, especially after brain tumours and/or cranial 
irradiation. However, well-conducted long-term studies on 
the safety of GH replacement therapy are lacking, and sev-
eral experimental studies raised concerns about cancer risk 
and long-term mortality. These questions are investigated in 
the European FP-7 project «Safety and Appropriateness of 
Growth hormone treatments in Europe» (SAGhE). 
 Objectives: The project investigates long-term efﬁca-
cy (ﬁnal height), health related quality of life (HRQoL) and 
long-term safety of GH-treatment in childhood, in particu-
lar the risk of cancer and/or mortality.
 Methods: Cohort study based on the population of pa-
tients who were treated with GH during childhood in Swit-
zerland since 1985. Eligible patients were identiﬁed from 
paediatric endocrinology centres in Switzerland; the SCCR 
and the Swiss Paediatric Renal Registry, and databases from 
pharmaceutical companies. Relevant data were extract-
ed from hospital records. Quality of life was assessed by a 
questionnaire. Incident cancers were assessed via linkage 
with the SCCR and cantonal cancer registries. Date and 
place of death were obtained via municipal population reg-
isters, cause of death from the mortality statistics. Risk of 
cancer and mortality in the cohort were compared to the 
risk in the general population by calculating standardized 
incidence ratios and standardized mortality ratios.
 Rationale and signiﬁcance: The project describes the 
use of GH in Switzerland and analyses long-term safety in 
the context of a high-quality international collaborative 
study. Results will likely inﬂuence future recommendations 
for treatment with GH in children. 
 Current status of project: We identiﬁed 1884 patients 
treated with GH during childhood. Patients older than 18 
years were included in the SAGhE study (N=754). We as-
sessed health related quality of life for patients over 18 years 
via a postal questionnaire. A total of 687 patients were eligi-
ble and 415 (60%) replied. All data have been sent to work 
package leaders and publications are expected in 2015.
 Study team: Kuehni CE, Sommer G, Kuonen R. Insti-
tute of Social and Preventive Medicine, University of Bern; 
Mullis PE. University Children’s Hospital, Inselspital Bern.
 Funding: European Union FP7 (Grant No HEALTH-F2-
2009-223497), Swiss Cancer League (Grant No KLS-02586-
02-2010 and KLS-2948-02-2012).
 Contact: Claudia Kuehni (claudia.kuehni@ispm.unibe.ch), 
Grit Sommer (grit.sommer@ispm.unibe.ch)
28
4.6 Mortality and Second Primary Cancers 
 after Cancer in Childhood and Adolescence
 Background: Despite improved cure rates, childhood 
cancer remains the most common disease related cause of 
death in childhood. In the ﬁrst 10 years after diagnosis the 
primary cancer is the main cause of death, but thereafter 
deaths from second primary cancers and chronic diseases 
predominate.
 Objectives: This project aims to: 1) analyse survival and 
factors associated with survival after cancer in childhood; 
2) analyse total and cause-speciﬁc mortality, including late 
mortality (>5 years after diagnosis of cancer) after cancer in 
childhood. 
 Methods: This study uses data from all children di-
agnosed with cancer in Switzerland. Vital status and date 
of death are updated via municipal population registries. 
Cause of death is available from the Swiss mortality sta-
tistics. We estimate survival at 5, 10 and 20 years after 
diagnosis, overall and stratiﬁed by diagnosis, and analyse 
time trends in survival. We examine determinants of sur-
vival (sex, type of childhood cancer, tumour histology, age 
at diagnosis, treatment modalities, region of residence, so-
cio-economic position). For aim 2 we calculate overall and 
cause-speciﬁc standardized morality ratios (SMR) and abso-
lute excess risks (AER), cumulative mortality and risk factors 
for speciﬁc causes of death.
 Rationale and signiﬁcance: This project provides the 
ﬁrst national data on survival and long-term mortality af-
ter cancer in childhood in Switzerland. Knowledge about 
avoidable risk factors for premature death will help to de-
velop improved treatments. 
 Current status of project: Analysis is ongoing and 2 
publications are being written. 
 Study team: Kuehni CE, Schindler M, Institute of Social 
and Preventive Medicine University of Bern; Michel G, De-
partment of Health Sciences and Health Policy, University of 
Lucerne
 Funding: Swiss National Science Foundation (PD-
FMP3_141775), Swiss Bridge
 Contact: Claudia Kuehni (claudia.kuehni@ispm.unibe.ch),
Matthias Schindler (matthias.schindler@ispm.unibe.ch)
 Publications: Expected for 2015
4.7 Fertility after Chemo- and Radiotherapy 
 in Childhood and Adolescence, 
 FeCt – Multicentre Offspring Study
 Background: Similar to the general population many 
former childhood cancer patients wish to have children. 
However, many survivors worry that their own children 
might develop cancer or could have other health problems. 
These fears can affect the quality of life and family plan-
ning. Previous studies found no increased risk for genetic 
diseases or cancers. However, most studies only included 
small numbers of survivors with their own children. There-
fore, the SCCR participates in an international multicentre 
study including Germany [Principal Investigator], Austria, 
Poland, Czech Republic and Switzerland.
 Objectives: In order to provide better information and 
education of patients and survivors of childhood cancer we 
aim to answer the following questions: 1. Is there a differ-
ence in the general health status of the offspring of former 
childhood cancer patients compared to children in the gen-
eral population? 2. How concerned are former childhood 
cancer patients regarding their children? 3. How healthy do 
children of former childhood cancer patients grow up?
 Methods: In this cross-sectional study we include all 
former patients registered at the SCCR who were diag-
nosed with cancer under age 16 years, were Swiss residents 
at diagnosis, are now at least 18 years old and have own 
children. In addition, we invite siblings of participating sur-
vivors to complete a questionnaire for their children. The 
questionnaire was developed in Germany and includes 
questions on the health status of the offspring, and con-
cerns of survivors regarding their children.
 Rationale and signiﬁcance: The proposed study will 
provide a better basis for the education of former, current 
and future patients. Fears of former cancer patients can be 
addressed and reduced if valid and adequate information is 
available. Where required, preventive measures to improve 
health impairment in offspring can be taken.
 Current status of the project: We are currently pre-
paring the questionnaire survey.
 Study team: Michel G, Vetsch J, Rueegg CS, Depart-
ment of Health Sciences and Health Policy, University of Lu-
cerne 
 Funding: Kinderkrebshilfe Schweiz.
 Contact: Gisela Michel (gisela.michel@unilu.ch), Janine 
Vetsch (janine.vetsch@unilu.ch)
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4.8 Parents of Long-Term Childhood Cancer 
 Survivors
 Background: When a child is diagnosed with cancer, 
parents are confronted with the potential fatality of the dis-
ease. They experience a highly stressful time, which may 
affect their psychological well-being, their relationship as 
a couple, and with their children. Additionally, because of 
prolonged absence from work, they may experience an 
economic burden. However, for many parents distress is not 
over with the end of treatment and the cure of their child. 
Parents may suffer from a variety of psychological problems 
such as depression, anxiety or post-traumatic stress symp-
toms. Uncertainty about their child’s health and worries 
about a possible relapse or late effects may negatively affect 
parents individually or as a couple. So far, late outcomes of 
childhood cancer in parents have mostly been studied in 
small samples and only within a short time frame after the 
end of treatment.
 Objectives: We aim to 1) describe psychological and 
socio-demographic outcomes, as well as needs in parents 
of long-term childhood cancer survivors and compare them 
with parents of the general population, 2) evaluate associ-
ations of these outcomes with the clinical characteristics of 
the child’s disease and the child’s own late outcomes and 
3) provide Swiss norm-data for established and frequently 
used instruments on quality of life, psychological distress 
and post-traumatic stress.
 Methods: We will include all parents whose children 
were diagnosed with cancer under age 16 years, who were 
Swiss residents at diagnosis, who survived for 5 years or 
more, and are currently alive and aged 20 years or older. 
Additionally, we will select a random sample of parents 
from the general population. Parents of survivors will ﬁrst 
be contacted by paediatric oncologists from the original 
treating clinic. All parents will receive a questionnaire pack-
age from the study centre. Clinical information on the can-
cer and treatment are available from the SCCR, and infor-
mation about survivors’ health from the Swiss Childhood 
Cancer Survivor Study.
 Rationale and signiﬁcance: Several large cohort stud-
ies among childhood cancer survivors have improved our 
knowledge on their late outcomes and well-being. How-
ever, while most survivors get on with their life after can-
cer, many parents remain affected by their experience long 
after their child reaches adulthood. The proposed study 
will be the ﬁrst population-based study among parents of 
long-term survivors of childhood cancer and will shed light 
on their psychological well-being, social outcomes and the 
needs they have for their children and themselves.
 Current status of the project: The new question-
naire including questions on quality of life, post-traumatic 
growth, family bonding and social consequences has been 
developed and we are currently preparing the documents 
for the submission to the ethics committee. 
 Study team: Michel G, Vetsch J, Rueegg CS, Depart-
ment of Health Sciences and Health Policy, University of Lu-
cerne 
 Funding: Swiss National Science Foundation (Grant-
No: 100019_153268 / 1), Kinderkrebshilfe Schweiz.
 Contact: Gisela Michel (gisela.michel@unilu.ch), Janine 
Vetsch (janine.vetsch@unilu.ch)
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4.9 Effectiveness of Transition from Paediatric  
 to Adult Care after Childhood Cancer
 Background: Transition from paediatric to adult care 
is a crucial step in many chronic diseases of childhood. 
Treatments in paediatric oncology have improved over the 
past decades; now about 80% of patients survive to adult-
hood. However, 60% suffer from adverse somatic or psy-
chosocial late effects from the cancer and its treatments 
and necessitate long-term follow-up. Generally, follow-up 
is well organised during the ﬁrst 5-10 years after diagnosis, 
and often occurs in the context of a clinical trial. However, 
transfer of patients to adult care often fails, and survivors 
may be lost to follow-up or continue to visit their paediatric 
institution despite their adult status and changing needs. 
 Objectives: The project aims to: 1) determine the fre-
quency of follow-up in childhood cancer survivors when 
they are in paediatric care; 2) describe transfer modalities; 
3) describe the health care providers involved in follow-up 
and transfer; 4) determine factors associated with success-
ful transfer; and 5) describe the advantages and disadvan-
tages of different kinds of follow-up for survivors, families 
and health care providers from paediatric and adult wards. 
 Method: This study analyses information collected from 
medical records on follow-up care, transitional care and 
transfer to adult care. Additional information on current 
follow-up, socio-economic characteristics and late effects 
comes from two separate, on-going questionnaire studies 
(Swiss Childhood Cancer Survivor Study and Childhood 
Cancer Follow-Up Study). 
 Rationale and Signiﬁcance: The available information 
will be used to develop the ﬁrst national guidelines for the 
transition of childhood cancer survivors. In addition, results 
will provide a basis for the improvement of transitional care 
for other chronic diseases. 
 Current status of project: All data have been collect-
ed and are now being analysed. 
 Study team: Michel G, Gianinazzi ME, Department of 
Health Sciences and Health Policy, University of Lucerne
 Funding: Swiss Cancer League (Grant No KFS-02631-
08-2010)
 Publications: Expected for 2015.
 Contact: Gisela Michel (gisela.michel@unilu.ch)
4.10 Childhood Cancer and Vicinity of 
 Residence to Petrol Stations and Roads:  
 Census-Based Nationwide Cohort Study  
 (PETROL)
 Background: Benzene is a common air-pollutant; it is 
haematotoxic and an established human carcinogen. Its as-
sociation with acute myeloid leukaemia is well documented 
in adults but data on children are scarce. To our knowledge, 
no cohort studies have investigated potential associations 
between benzene exposure and childhood cancer in chil-
dren.
 Objective: To examine whether 1) residence in the 
proximity of petrol stations, motor vehicle service stations 
or major roads, and 2) parental profession-related exposure 
to benzene are associated with a higher risk of cancer, par-
ticularly leukaemia, in children and adolescents.
 Methods: The study includes all children born between 
January 1985 and December 2008, aged 0-15 years at di-
agnosis of cancer or leukaemia and resident in Switzerland 
(N=5300). Data on these children were obtained from the 
Swiss National Cohort (SNC), a long-term, census-based 
cohort that includes all Swiss inhabitants. Diagnosed cases 
of cancer were identiﬁed from the SCCR. Geocoded places 
of residence were used to assess proximity to petrol sta-
tions, motor vehicle service stations and major roads. We 
considered place of residence at birth and at diagnosis sep-
arately. Data on parental occupation during the 1990 and 
2000 censuses were obtained from the SNC. Using a job 
exposure matrix we identiﬁed children whose parents were 
exposed to benzene at work. The data were analysed using 
Poisson regression and Cox proportional hazard models, 
adjusting for a range of potential confounders including 
socio-economic status, background ionizing radiation and 
birth weight.
 Rational and Signiﬁcance: Trafﬁc-related pollution, 
including benzene, and its effects on health are a major 
public health problem because a substantial proportion of 
the population is exposed. This unique, large-scale study 
will help clarify whether trafﬁc-related air pollution and ex-
posure to benzene in particular, contribute to the incidence 
of childhood cancer in the general population.
 Current status of project: Analyses have been com-
pleted and results are currently being written up and sub-
mitted for publication. 
 Study team: Spycher BD, Kuehni CE. Institute of Social 
and Preventive Medicine, University of Bern.
 Funding: Swiss Federal Ofﬁce of Public Health (BAG 
10.002946)
 Contact: Ben Spycher (ben.spycher@ispm.unibe.ch), 
Claudia Kuehni (claudia.kuehni@ispm.unibe.ch)
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4.11 Childhood Cancer and Geographically 
 Deﬁned Exposures in Switzerland: 
 A Census-Based Nationwide Cohort Study
 Background: Ionising radiation is the only environmen-
tal exposure that has been clearly linked to cancer in chil-
dren. It is, however, still unclear whether the dose-response 
relationships found in studies of persons exposed to mod-
erate or high doses can be extrapolated to the lower doses 
from background radiation. 
 Objective: To examine the risk of cancer in children and 
adolescents associated with exposure to background ionis-
ing radiation from cosmic and terrestrial sources.
 Methods: The study included all children born be-
tween January 1985 and December 2008, aged 0-15 years 
at diagnosis and resident in Switzerland (N=5300). Data on 
these children were obtained from the Swiss National Co-
hort (SNC), a long-term, census-based cohort that includes 
all Swiss inhabitants. Diagnosed cases of cancer were iden-
tiﬁed from the SCCR. Based on previously developed ra-
diation maps we determined dose rates of ionising radia-
tion (unit: nSv/h) from cosmic rays and terrestrial gamma 
rays at places of residence. We considered both the place 
of residence at birth and at diagnosis. We investigated 
the following outcomes: all childhood cancer, leukaemia, 
acute lymphoid leukaemia, acute myeloid leukaemia, and 
tumours of the central nervous system (CNS). Associations 
between outcomes and radiation dose rates were assessed 
using Poisson regression and Cox proportional hazard mod-
els, adjusting for a range of potential confounders including 
socio-economic status, proximity to highways and power 
lines, and birth weight.
 Rationale and Signiﬁcance: It is well known that ion-
izing radiation at moderate to high doses causes cancer in 
humans. What remains unclear is whether protracted ex-
posure to radiation at low dose rates, such as exposure to 
natural background radiation, contributes to cancer risk 
in the population at large. With the SCCR and the SNC 
we have the rare opportunity to study exposure to natural 
background radiation in a nationwide cohort study. In ad-
dition, exposure to natural background radiation has a rel-
atively high variation in Switzerland, because of differences 
in altitude between residential locations.
 Current status of project: The analyses have been 
completed and a manuscript has been submitted for publi-
cation.
 Study team: Spycher BD, Kuehni CE. Institute of Social 
and Preventive Medicine, University of Bern.
 Funding: Swiss Federal Ofﬁce of Public Health (BAG 
12.008357)
 Contact: Ben Spycher (ben.spycher@ispm.unibe.ch), 
Claudia Kuehni (claudia.kuehni@ispm.unibe.ch)
 Publications: 
Spycher BD et al. Environ Health Perspect. in press. 2014
4.12 The Role of Population Mixing and 
 Exposure to Infections in the 
 Aetiology of Childhood Leukaemia: 
 A National Cohort Study
 Background: Leukaemia is the most important cancer 
among children in industrialized countries. Infections may 
play a role: the incidence of acute lymphoic leukaemia (ALL) 
is higher in resource-rich countries, where infections early 
in life are less common compared to resource-poor settings; 
there is a sharp peak in incidence at 2-5 years of age; local 
clusters of cases have been described and there is seasonal 
variation in the diagnosis of ALL. Kinlen proposed that pop-
ulation mixing, i.e. large inﬂuxes of people into previously 
isolated areas, could explain clusters of childhood leukae-
mia. Childhood leukaemia may thus be a rare response to 
a common, yet unidentiﬁed, infection. Greaves proposed 
the delayed-immune hypothesis as an explanation for the 
peak incidence of ALL at 2-5 years: a lack of exposure to 
infections in early life could predispose the immune system 
to aberrant responses to subsequent ‘delayed’ infections.
 Aims: To determine whether leukaemia (any leukaemia 
and ALL) diagnosed at age <20 years is associated with the 
following measures of population mixing at community lev-
el (Kinlen’s hypothesis): 1) volume and diversity of incoming 
migrants into communities, and 2) change in annual in-mi-
gration; or with proxy measures of exposure to infections 
(Greaves’ hypothesis): 3) birth order, 4) child density in the 
neighbourhood, and 5) extra-familial child-care.
 Methods: The study uses data from the Swiss National 
Cohort (SNC), the Swiss Childhood Cancer Registry (SCCR), 
the Swiss cytogenetic database (SCD) and demographic 
data from the Swiss Federal Statistical Ofﬁce. Primary out-
comes are any leukaemia and ALL in particular. Second-
ary outcomes are the most prevalent immunophenotype, 
B-cell-precursor ALL, and cytogenetic subgroups like high 
hyperdiploidy and TEL-AML1 translocation. Main exposures 
are percentage of the population that moved into a com-
munity within the last 5 years, diversity of areas of origin 
(Shannon’s entropy), change in annual volume of incoming 
migrants relative to average in previous years, the rank of 
the child among all live births of the same mother, neigh-
bourhood indices of child density developed using road net-
work connectivity, and parental full-time employment as a 
proxy measure of extra-familial child-care. 
 Rationale and Signiﬁcance: The possibility that child-
hood leukaemia might be associated with a speciﬁc infec-
tion or with later exposure to infections is highly relevant 
for prevention. Previous studies were limited by the lack of 
spatial or temporal precision and few studies were able to 
use both residential locations at birth and at diagnosis. In 
the present study only routine databases with national cov-
erage will be used and precise geocoding of the address at 
both birth and at diagnosis will allow high temporal and 
spatial resolution.
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 Current status of project: Analyses is ongoing and re-
sults for a ﬁrst publication are currently being written up. 
 Study team: Spycher BD, Kuehni CE, Lupatsch JE, Kreis 
C. Institute of Social and Preventive Medicine, University of 
Bern.
 Funding: Cancer Research Switzerland (Grant No KFS-
3049-08-2012)
 Contact: Ben Spycher (ben.spycher@ispm.unibe.ch)
4.13 The Spatial Epidemiology of Childhood 
 Cancer in Switzerland
 Background: Childhood cancer is a major cause of 
death in children but the associated risk factors are still 
largely unknown. Numerous environmental causes, such 
as background ionising radiation, air pollution, or electro-
magnetic ﬁelds have been suspected and infections in early 
life may also play a role. Many of these hypotheses imply 
a spatially heterogeneous distribution of cancer incidence, 
making them potentially testable with methods of spatial 
epidemiology. For instance, the putative effects of cosmic 
ionizing radiation could lead to detectable differences in in-
cidence according to altitude, particularly in a mountainous 
country like Switzerland. Outbreaks of infections caused by 
a rapid inﬂux of people into an isolated area could lead to 
clusters of cancer cases.
 Aims: This study aims to investigate 1) whether the inci-
dence of childhood cancer in Switzerland during the period 
1985 to present was associated with natural ionizing radia-
tion (cosmic, terrestrial, domestic radon) and trafﬁc related 
air pollution, and whether there is an interaction between 
trafﬁc related air pollution and domestic radon 2) whether 
the incidence of childhood cancer was elevated in commu-
nities that experienced rapid population inﬂuxes (popula-
tion mixing) and 3) whether there is evidence for a general 
tendency of cases to cluster in space and in space and time.
 Methods: This study includes the entire Swiss resident 
population aged <20 years. Data on cancer diagnoses in 
this population will be obtained from the SCCR and data on 
the population at risk from the SNC. Outcomes will be any 
childhood cancer and major diagnostic subgroups such as 
leukaemia, lymphomas, and tumours of the central nervous 
system. Among leukaemias, we will separately investigate 
acute lymphoblastic leukaemia (ALL), and important cyto-
genetic subtypes of ALL. Dose rates of outdoor cosmic and 
terrestrial ionising radiation at places of residence will be 
estimated from existing radiation maps and indoor radon 
gas concentrations using a previously developed prediction 
model. Proxy measures for trafﬁc related air pollution will 
include distance of place of residence to near major roads, 
to nearest petrol stations or motor vehicle service stations, 
and predicted outdoor concentrations of speciﬁc pollut-
ants. 
 Signiﬁcance: The planned work will advance impor-
tantly our understanding of the role of environmental risk 
factors (or the lack thereof) in the aetiology of childhood 
cancer.
 Current status of project: Analyses is ongoing.
 Study team: Spycher BD, Kreis C, Kuehni CE, Institute 
of Social and Preventive Medicine, University of Bern.
 Funding: Swiss National Science Foundation (Ambi-
zione, Grant Nr. 147987)
 Contact: Ben Spycher (ben.spycher@ispm.unibe.ch)
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All articles published using SCCR data from January 
2006 – December 2014 are reported below. Additional 
publications related to the SCCR or SPOG can be found on 
the SCCR and SPOG websites: www.childhoodcancerregis-
try.ch and www.spog.ch.
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International Classiﬁcation of Childhood Cancer - 
ICCC-3
The third edition of the International Classiﬁcation of 
Childhood Cancer (ICCC-3) represents the standard for 
presentation of international data on childhood cancer in-
cidence and survival. It applies the rules, nomenclature and 
codes (morphology, topography and behaviour) of the ICD -
O-3. ICCC-3 categories are deﬁned in conformity with in-
ternational classiﬁcations of the pathology and genetics of 
childhood cancers. In the ICCC-3, three hierarchical levels 
have been developed: level one consists of 12 main diag-
nostic groups and level two of 47 diagnostic subgroups. 
These two levels of the ICCC-3 allow standardised com-
parison of the broad categories of childhood tumours. Lev-
el three, an optional «extended» classiﬁcation, comprises 
two to eleven divisions of selected diagnostic subgroups. 
The division of some diagnostic subgroups, e.g. leukae-
mia and Non-Hodgkin lymphomas, reﬂects the availability 
of detailed cytogenetic or molecular information that per-
mits homogeneous groups of tumours to be distinguished 
within them and thus allows their separate study. The Swiss 
childhood cancer registry (SCCR) uses level one to three. 
Only malignant neoplasms are classiﬁed in ICCC-3, with 
the exception of non-malignant intracranial and intraspinal 
tumours. Tumours known to occur only rarely in young pa-
tients are also included in ICCC-3. The ICCC-3 is used if 
data are compared with other childhood cancer registries.
International Statistical Classiﬁcation of Diseases 
for Oncology - ICD-O-3
The third edition of the International Statistical Classi-
ﬁcation of Diseases for Oncology (ICD-O-3) has been de-
veloped by a working group hosted by the International 
Association of Research in Cancer (IARC) and WHO. The 
morphology code for neoplasm has been revised, especial-
ly for lymphomas and leukaemia. In contrast to the Inter-
national Classiﬁcation of Diseases, 10th revision (ICD-10), 
ICD-O-3 uses only one set of four characters for topography 
(based on the malignant neoplasm section of ICD-10). The 
topography code remains the same for all neoplasms of that 
site. The behaviour code is incorporated as the ﬁfth digit in 
the morphology ﬁeld. It identiﬁes whether the tumour is 
malignant, benign, of uncertain or unknown behaviour, in 
situ, presumed to be primary or secondary. For all tumours 
diagnosed since 1st January 2014 the SCCR uses the 2011 
updates to ICD-O-3 which include new terms, codes and 
behaviour combinations. This allows e.g. B lymphoblastic 
leukaemias to be further classiﬁed according to their exact 
cytogenetic and molecular characteristics, which are rele-
vant for disease prognosis. ICD-O-3 is used to compare data 
with general cancer registries.
International Statistical Classiﬁcation of Diseases 
and Related Health Problems - ICD-10
The International Statistical Classiﬁcation of Diseases 
and Related Health Problems (ICD) permits the systematic 
recording, analysis, interpretation and comparison of mor-
tality and morbidity data collected in different regions and 
at different time periods. The ICD has become the inter-
national standard diagnostic classiﬁcation for all general 
epidemiological purposes. The ICD-10 classiﬁcation com-
prises three volumes: Volume 1 contains the main classiﬁ-
cations; Volume 2 provides guidance for users of the ICD; 
and Volume 3 is the alphabetical index to the classiﬁcation. 
Classiﬁcation is divided into 21 chapters. The ﬁrst character 
of the ICD code is a letter. Each letter is associated with a 
particular chapter, e.g. the letter D is used in both chapter 
II «Neoplasms» and chapter III «Diseases of the blood and 
blood-forming organs and certain disorders involving the 
immune mechanism». The topography code in Volume 3 
describes the site and the behaviour of the neoplasm: ma-
lignant, secondary or metastatic, in situ, benign or of un-
known behaviour. The morphology codes listed in Volume 1 
are the same as those used in the special adaptation of the 
ICD for oncology, the ICD-O97.
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